Cytokinetics CYTK
NASDAQ CYTK
$62.86 -1.09 (-1.70%)
At close: Oct 21, 2026 · 4:00 PM EDT

Cytokinetics (CYTK) Gross Margin (2025 - 2026)

Updated

Cytokinetics (CYTK) recorded Gross Margin of 90.46% in Q2 2026, down 9.54 percentage points from 100.00% a year earlier and down 8.71 percentage points from the prior quarter.

Analysis

Cytokinetics (CYTK) Gross Margin (2025 - 2026) Analysis & Trends

On a TTM basis, Cytokinetics' Gross Margin came in at 167.63% as of Jun 30, 2026.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 85.78%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 68.19%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 74.74%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 73.54%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 78.02%
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 83.60%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 72.04%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 79.76%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 72.78%
10 Cytokinetics 8.30 Bn 4.48 Bn 25.89 Mn 90.46%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 90.46%
Mar 31, 2026 99.17%
Jun 30, 2025 100.00%
Mar 31, 2025 100.00%
API Access

Cytokinetics Gross Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gross-margin&ticker=CYTK&period=max&api_key=YOUR_API_KEY